Adicet Bio Inc - Asset Resilience Ratio

Latest as of June 2026: 57.41%

Adicet Bio Inc (ACET) has an Asset Resilience Ratio of 57.41% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Adicet Bio Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$85.06 Million
Cash + Short-term Investments

Total Assets

$148.17 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2008–2025)

This chart shows how Adicet Bio Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Adicet Bio Inc asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Adicet Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Adicet Bio Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $85.06 Million 57.41%
Total Liquid Assets $85.06 Million 57.41%

Asset Resilience Insights

  • Very High Liquidity: Adicet Bio Inc maintains exceptional liquid asset reserves at 57.41% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Adicet Bio Inc Industry Peers by Asset Resilience Ratio

Compare Adicet Bio Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ALK-Abelló A/S
CO:ALK-B
Biotechnology 0.98%
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Biotechnology 6.89%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
Biotechnology 10.55%

Annual Asset Resilience Ratio for Adicet Bio Inc (2008–2025)

The table below shows the annual Asset Resilience Ratio data for Adicet Bio Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 62.18% $119.61 Million $192.35 Million +7.78pp
2024-12-31 54.40% $119.81 Million $220.22 Million --
2023-12-31 0.00% $0.00 $207.29 Million --
2021-12-31 0.00% $0.00 $338.94 Million --
2020-12-31 6.69% $10.28 Million $153.84 Million -56.80pp
2019-12-31 63.48% $51.79 Million $81.59 Million -28.37pp
2018-12-31 91.86% $100.99 Million $109.94 Million +88.15pp
2017-12-31 3.71% $2.05 Million $55.19 Million +3.54pp
2016-12-31 0.16% $881.00K $540.78 Million -0.53pp
2015-12-31 0.70% $3.42 Million $489.77 Million +0.54pp
2014-12-31 0.16% $746.00K $467.98 Million -0.50pp
2013-12-31 0.66% $2.14 Million $323.43 Million +0.16pp
2012-12-31 0.51% $1.52 Million $299.28 Million +0.19pp
2011-12-31 0.32% $943.00K $294.99 Million +0.16pp
2010-12-31 0.15% $335.00K $216.56 Million -0.13pp
2009-12-31 0.29% $541.00K $189.27 Million +0.02pp
2008-12-31 0.27% $548.00K $205.50 Million --
pp = percentage points

About Adicet Bio Inc

NASDAQ:ACET USA Biotechnology
Market Cap
$84.35 Million
Market Cap Rank
#19921 Global
#4551 in USA
Share Price
$9.01
Change (1 day)
-0.44%
52-Week Range
$0.47 - $9.73
All Time High
$145.95
About

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more